Target Name: LOC105373649
NCBI ID: G105373649
Review Report on LOC105373649 Target / Biomarker Content of Review Report on LOC105373649 Target / Biomarker
LOC105373649
Other Name(s): LOC105373649 variant X1 | LOC105373649 variant X2 | uncharacterized LOC105373649 | Uncharacterized LOC105373649, transcript variant X1 | Uncharacterized LOC105373649, transcript variant X2 | Uncharacterized LOC105373649, transcript variant X3 | LOC105373649 variant X3

LOC105373649: A Potential Drug Target or Biomarker

LOC105373649 (LOC105373649 variant X1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the heat shock protein (HSP) family, which are proteins that are expressed in response to increased levels of thermal stress in the body.

HSPs are known for their ability to survive and function in extreme conditions, such as high temperatures and radiation. They are also involved in the regulation of cellular processes that are critical for cell survival, such as the regulation of inflammation and the detoxification of harmful substances.

LOC105373649 variant X1 is a specific variant of the HSP protein that has been identified as a potential drug target or biomarker. This protein is known for its ability to interact with several different drugs, including chemotherapy drugs and anti-inflammatory drugs.

One of the unique features of LOC105373649 is its ability to interact with the drug doxorubicin, which is a chemotherapy drug that is commonly used to treat various types of cancer. doxorubicin is known for its ability to cause DNA damage to cells, which can lead to the inhibition of cell growth and the death of cancer cells.

LOC105373649 has been shown to interact with doxorubicin in a number of different ways. For example, studies have shown that LOC105373649 can inhibit the activity of doxorubicin by interacting with its calbindin-binding protein (CBP). CBP is a protein that is known for its ability to bind to doxorubicin and can protect cells from the toxic effects of doxorubicin.

In addition to its ability to interact with doxorubicin, LOC105373649 has also been shown to interact with several other drugs that are commonly used to treat various types of cancer. For example, studies have shown that LOC105373649 can interact with the drug lenvastatin, which is a cholesterol-lowering drug that is commonly used to treat heart disease.

LOC105373649 variant X1 has also been shown to interact with the drug adalimumab, which is a type of anti-inflammatory drug that is commonly used to treat rheumatoid arthritis and other inflammatory conditions.

The potential drug targeting and biomarker properties of LOC105373649 make it an interesting candidate for further research. Further studies are needed to determine the full extent of its potential drug targeting and biomarker properties, as well as the underlying mechanisms that are responsible for its interactions with doxorubicin and other drugs.

In conclusion, LOC105373649 (LOC105373649 variant X1) is a protein that has been identified as a potential drug target or biomarker. Its ability to interact with doxorubicin and other drugs that are commonly used to treat various types of cancer makes it an interesting candidate for further research. Further studies are needed to fully understand its drug targeting and biomarker properties, as well as the underlying mechanisms that are responsible for its interactions with these drugs.

Protein Name: Uncharacterized LOC105373649

The "LOC105373649 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105373649 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105373652 | LOC105373657 | LOC105373659 | LOC105373660 | LOC105373677 | LOC105373696 | LOC105373703 | LOC105373707 | LOC105373710 | LOC105373712 | LOC105373717 | LOC105373723 | LOC105373730 | LOC105373750 | LOC105373751 | LOC105373759 | LOC105373781 | LOC105373796 | LOC105373831 | LOC105373835 | LOC105373836 | LOC105373874 | LOC105373882 | LOC105373891 | LOC105373918 | LOC105373920 | LOC105373937 | LOC105374007 | LOC105374009 | LOC105374020 | LOC105374025 | LOC105374033 | LOC105374036 | LOC105374037 | LOC105374041 | LOC105374060 | LOC105374089 | LOC105374107 | LOC105374140 | LOC105374174 | LOC105374187 | LOC105374193 | LOC105374207 | LOC105374210 | LOC105374211 | LOC105374217 | LOC105374218 | LOC105374224 | LOC105374226 | LOC105374234 | LOC105374265 | LOC105374287 | LOC105374294 | LOC105374300 | LOC105374316 | LOC105374318 | LOC105374320 | LOC105374325 | LOC105374329 | LOC105374341 | LOC105374344 | LOC105374362 | LOC105374364 | LOC105374377 | LOC105374378 | LOC105374421 | LOC105374428 | LOC105374432 | LOC105374434 | LOC105374456 | LOC105374494 | LOC105374497 | LOC105374505 | LOC105374506 | LOC105374514 | LOC105374521 | LOC105374522 | LOC105374523 | LOC105374524 | LOC105374527 | LOC105374533 | LOC105374535 | LOC105374553 | LOC105374584 | LOC105374591 | LOC105374595 | LOC105374608 | LOC105374610 | LOC105374613 | LOC105374645 | LOC105374660 | LOC105374683 | LOC105374701 | LOC105374713 | LOC105374724 | LOC105374726 | LOC105374736 | LOC105374737 | LOC105374754 | LOC105374756